China Nepstar Chain Drugstore to Announce Fourth Quarter 2007 Financial Results o...(ts. Such statementsinvolve certain risks...),Health
Navigation Links
China Nepstar Chain Drugstore to Announce Fourth Quarter 2007 Financial Results on March 19
Date:3/10/2008
ts. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its registration statement on Form F-1. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
For more information, please contact:
In China:
Lucia Qian
Marketing and IR Director
China Nepstar Chain Drugstore Ltd.
Tel: +86-755-2641-4065
Email: qianrt@nepstar.cn
In the United States:
Dixon Chen
Investor Relations
The Global Consulting Group
Tel: +1-646-284-9403
Email: dchen@hfgcg.com
Ivette Almeida
Media Relations
The Global Consulting Group
Tel: +1-646-284-9455
Email: ialmeida@hfgcg.com
'/>"/>
| SOURCE China Nepstar Chain Drugstore Ltd. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Wyeth to Invest $280 Million to Build State-of-the-Art Nutritional Manufacturing Facility in China
2. Smoking is major risk factor for stroke in China
3. China Nepstar Chain Drugstore to Implement SAP ERP Solution to Optimize Management and Cost Controls and Enhance Operating Efficiencies
4. China Sky One Medical, Inc. Appoints Four Independent Board Members
5. China Sky One Medical, Inc. to Acquire Heilongjiang Tianlong Pharmaceutical, Inc.
6. China Medical Technologies Reports Third Quarter Financial Results
7. China Nepstar Chain Drugstore to Acquire 68 Drugstores from Ningbo New Century Medical Ltd.
8. China Bionanometer Industries Corporation Announces New Products for China
9. China Dongsheng International Announces Fiscal Year 2008 Second Quarter Financial Results
10. Mix-Up Behind FDAs Failure to Inspect China Blood-Thinner Plant
11. China Holdings Announces Starwood Research Institute Initiates Research Coverage
Post Your Comments:
(Date:11/21/2009)...1 Milvia Lopez, by her attorney MI...filed suit, in Supreme Court, New York County, bea...at while Ms. Lopez underwent a routine transesopha...ITAL , doctors used an HIV infected scope exposing...veral hours after being discharged from the proced...
(Date:11/21/2009)... based medical credentialing software company Inte... a partnerhsip with Amerinet, Inc., the leading he... help to transform quality care within the healthc...ember 21, 2009 -- ISG Group, LLC, doing business a... with Amerinet Inc., a leading national healthcare...
(Date:11/21/2009)...w Haven Dental Group merges their practice with th... (PRWEB) November 21, 2009...ers Dr. David Gibson, Dr. Dean Cloutier, Dr. John ... their growing practice with that of esteemed coll...decided he wanted to retire from dentistry in orde...
(Date:11/20/2009).... 20 The American Acad...ealth care reform legislation released this week t...urance individual coverage mandate. The actuaries ...l minimize adverse selection stemming from more re... bill. ,, "The individual mandate language shou...
(Date:11/20/2009)... Nov. 20 Rates of infect...ed in late October, but the pandemic flu virus con...age groups, including the elderly, according to a ...: DGX ), the world,s leading provider of diagnos...ts most recent Quest Diagnostics Health Trends(TM)...
Breaking Medicine News(10 mins):Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:New Haven Dental Group Expands Their Vision 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3[0] Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure[0] IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care[0] New Haven Dental Group Expands Their Vision [0] Actuaries to Senate: Strengthen Individual Mandate[0] H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics
...Roche announced today that a total of,20 U.S. and ...eloda(R),(capecitabine) have been accepted for pre...mposium (SABCS) in San AntonioDecember 12-14, incl...cts to be presented at the meeting compare the imp...
... 9 , The following is being issued by Norma... Recently there has been a frenzy of articles in...elivery system. We are told there are 46 million,p...care,rescue plan passed within ninety days of Pres...
... Voonami, Inc., a leading provider of outsourc...nounced today the opening of their first of severa...r in Orem, UT. Voonami also announced two new ada...ty of 300 watts per square foot. , ...
... Despite the recent economic downturn, natural...e industry are still experiencing a wellness boom,...rowth. Natural Healers, the Internet,s top natural... centers to help prospective students interested i...
... Full Spectrum - a leading FDA software develo...h the latest information on code obfuscation techn...able now. , (PRWEB) Decem... the impact of using a basic software engineering ...
...Therapeutics, Inc.,(Nasdaq and MTA: CTIC) announce...ter studies utilizing Zevalin(R) ([90Y]-ibritumoma... of Hematology (ASH) 50th Annual Meeting in,San Fr...initial treatment in,15 patients with advanced sta...
Other Medicine News:Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 2Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 3Health News:Average Americans Without Health Insurance Are Young and Healthy With Above Average Incomes 2Health News:Voonami, Inc. Announces Three New Adaptive Data Centers 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 3Health News:Aimed at Medical Device Makers, FDA Software Development Company Full Spectrum Releases Free Technical Report on Software Protection Technology 2Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 2Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 3Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 4Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 5Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer SymposiumAverage Americans Without Health Insurance Are Young and Healthy With Above Average IncomesVoonami, Inc. Announces Three New Adaptive Data Centers Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier Aimed at Medical Device Makers, FDA Software Development Company Full Spectrum Releases Free Technical Report on Software Protection TechnologyThree Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
(Date:11/20/2009)... 20 Soligenix, Inc. (OTC... formerly known as DOR BioPharma, Inc., a late-sta...has formed a consortium to develop thermostable te...ting vaccines. Soligenix received a $9.4 million g...fectious Diseases (NIAID), a division of the Natio...
(Date:11/19/2009)...PRNewswire/ -- In response to an ever-increasing n...medicines, Operation Pangea II, involving 24 count...alth Organization,s International Medical Products...ht the dangers of buying medicines online. ,, T...s of arrests and the seizure of thousands of poten...
(Date:11/19/2009)...Nov. 19 Alexza Pharmaceu... its corporate presentation will be webcast live d...nference on Wednesday, December 2, 2009 at 9:00 a.... from The New York Palace Hotel in New York and wi...t and CEO. ,, To access the live presentation...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics 3A From Concept to Implementation Conference 53480 1Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics 3A From Concept to Implementation Conference 53480 2Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics 3A From Concept to Implementation Conference 53480 3Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 1Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 2Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 3Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 4Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 5Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 1Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 2Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 3Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 4...y for XIENCE V with No,Late Stent Thrombosis or Ad... Years, BARCELONA, Spain, May 22, 2007 /PRNewswire...ST trial demonstrated no,additional Major Adverse ...s in patients treated with either Abbott,s XIENCE(...its MULTI-LINK,VISION(R) metallic coronary stent. ...
...tCall/ -- According to,study results presented tod...nual meeting, iloperidone, an investigational,atyp...akathisia,profile. Akathisia -- a debilitating sen...ity to sit still -- is a frequent side effect,of a...died by Vanda,Pharmaceuticals Inc. , a biopharmace...
Other Medicine Technology:Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 2Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 3Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 4Antipsychotic Iloperidone Results Show Favorable Akathisia Profile 2Antipsychotic Iloperidone Results Show Favorable Akathisia Profile 3Antipsychotic Iloperidone Results Show Favorable Akathisia Profile 4Antipsychotic Iloperidone Results Show Favorable Akathisia Profile 5Symbia T, TruePoint SPECTCT system
Symbia T6, True Point SPECT·CT system
RADIANCE
QUALICHECK+
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |